ArticleMedical oncology (Northwood, London, England)2026
Formulation development and preliminary biological evaluation of a menthol modified thermoresponsive tamoxifen sol-gel.
Article in Medical oncology (Northwood, London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Localized drug delivery strategies offer potential advantages in improving therapeutic concentration at tumor sites while minimizing systemic exposure. In this study, a thermoresponsive poloxamer based sol-gel system incorporating tamoxifen citrate with L-menthol was developed and characterized for potential intratumoral application. The formulation was prepared using the cold method and optimized through response surface methodology\. The optimized system exhibited rapid sol-gel transition at 38.5 °C with gelation time around 37s, acceptable syringeability, pH compatibility with mildly acidic tumor conditions, and uniform drug content (93-96%) with high encapsulation efficiency (88-93%). In vitro release studies demonstrated sustained tamoxifen release over 48 h, best described by the Korsmeyer-Peppas model (n = 0.366), indicating diffusion-controlled release. Physicochemical analyses (FTIR, DSC, XRD, SEM) confirmed drug excipient compatibility and partial amorphization within the polymeric matrix. Molecular docking provided preliminary insight into potential interactions with breast cancer associated proteins. In vitro cytotoxicity in MCF-7 cells showed reduced IC₅₀ values for the menthol containing formulation compared to tamoxifen alone. Acute toxicity evaluation in mice indicated acceptable short-term tolerability. Overall, this system represents a promising localized delivery platform warranting further mechanistic and in vivo efficacy investigations.
Indexed as
Identifiers
42467342What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.